Company profile: Agena Bioscience
1.1 - Company Overview
Company description
- Provider of molecular diagnostic genetic reagents and mass spectrometry-based analysis systems, including the MassARRAY System for high-throughput genetic analysis in pharmacogenomics, mutation profiling, liquid biopsy, and inherited disease testing; PGx panels and the VeriDose Core Panel; custom assay services; the Revolution Sample Prep System for cfDNA extraction; and the MassARRAY Insights reporting software network.
Products and services
- MassARRAY System: A mass spectrometry-based platform that delivers highly sensitive, cost-effective, high-throughput genetic analysis used in pharmacogenomics, mutation profiling, liquid biopsy, and inherited disease testing
- Custom Assay Services: Custom-designed panels are developed and optimized for the MassARRAY System based on specific SNPs or reference sequences
- VeriDose Core Panel: A 20-gene panel targeting relevant variants involved in drug metabolism, delivering genotype information for 68 SNPs/INDELs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Agena Bioscience
SeQure Dx
HQ: United States
Website
- Description: Provider of safety data and diagnostic platforms for on- and off-target CRISPR gene editing therapies. Offers NoteSeQ (ONE-seq) for profiling off-target sites, ScopeSeQ for validating candidate edits via next-generation sequencing, risk assessment across the development lifecycle, discovery/IND support, clinical trial patient risk management, and post-approval diagnostic management with patient and physician education.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SeQure Dx company profile →
Exiqon
HQ: Denmark
Website
- Description: Provider of Life Sciences and Diagnostics solutions, offering flexible RNA analysis research products used by academia, biotech and pharmaceutical companies worldwide to investigate gene activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exiqon company profile →
AccuraGen
HQ: United States
Website
- Description: Provider of cancer early detection solutions: a liquid biopsy platform using unique biochemistry and machine learning to extract cancer signals in plasma for treatment guidance, minimal residue disease detection, and early screening; and CLAmp-seq technology to detect multiple cancer signals in blood and analyze them with machine learning for multi-cancer early detection tests.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AccuraGen company profile →
ElevateBio
HQ: United States
Website
- Description: Provider of cell and gene-based therapy solutions, offering cGMP manufacturing and process development through BaseCamp; gene-editing capabilities with Life Edit; integrated technology platforms spanning gene editing, cell therapy enabling technologies, RNA engineering, and delivery; and development of in vivo and ex vivo therapeutic programs leveraging internal R&D and partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ElevateBio company profile →
Ethris
HQ: Germany
Website
- Description: Provider of mRNA therapeutics and LNP delivery solutions focused on respiratory diseases and vaccines. Offers the SNIM RNA platform for stabilized non-immunogenic mRNA therapies and the SNaP LNP platform for targeted, inhalable delivery. Pipeline includes ETH47, ETH42, and ETH45 for respiratory indications. Provides in-house and partnered manufacturing with HPLC-free processes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ethris company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Agena Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Agena Bioscience
2.2 - Growth funds investing in similar companies to Agena Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Agena Bioscience
4.2 - Public trading comparable groups for Agena Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →